R 56865

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 461065

CAS#: 104606-13-5

Description: R 56865 is an anti-ischaemic.

Chemical Structure

No image available
R 56865
CAS# 104606-13-5

Theoretical Analysis

MedKoo Cat#: 461065
Name: R 56865
CAS#: 104606-13-5
Chemical Formula: C23H28FN3OS
Exact Mass: 413.1937
Molecular Weight: 413.55
Elemental Analysis: C, 66.80; H, 6.82; F, 4.59; N, 10.16; O, 3.87; S, 7.75

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: R 56865; R-56865; R56865;

IUPAC/Chemical Name: N-(1-(4-(4-fluorophenoxy)butyl)piperidin-4-yl)-N-methylbenzo[d]thiazol-2-amine


InChi Code: InChI=1S/C23H28FN3OS/c1-26(23-25-21-6-2-3-7-22(21)29-23)19-12-15-27(16-13-19)14-4-5-17-28-20-10-8-18(24)9-11-20/h2-3,6-11,19H,4-5,12-17H2,1H3


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 413.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Pijl AJ, Van Wezel HB, Koolen JJ, Piek JJ, Koch K, Swaan A, David GK, Visser CA, Van Zwieten PA. The negative inotropic and chronotropic effects of intravenous R 56865 during percutaneous transluminal coronary angioplasty. Br J Clin Pharmacol. 1995 May;39(5):531-5. PubMed PMID: 7669490; PubMed Central PMCID: PMC1365061.

2: Pijl AJ, Hendriks MG, Kam KL, Paffendorf M, van Zwieten PA. Effects of R 56865 on postischemic ventricular function in isolated rat working heart preparations obtained from healthy, diabetic and hypertensive animals. Naunyn Schmiedebergs Arch Pharmacol. 1994 Jun;349(6):619-26. PubMed PMID: 7969513.

3: Wermelskirchen D, Gleitz J, Urenjak J, Wilffert B, Tegtmeier F, Peters T. Flunarizine and R 56865 suppress veratridine-induced increase in oxygen consumption and uptake of 45Ca2+ in rat cortical synaptosomes. Neuropharmacology. 1992 Mar;31(3):235-41. PubMed PMID: 1630592.

4: Koch P, Schneider J, Fruh C, Wilhelm D, Wilffert B, Peters T. Interaction between R 56865 and alpha-adrenoceptors in the pithed rat. Arch Int Pharmacodyn Ther. 1989 May-Jun;299:134-43. PubMed PMID: 2570552.

5: Vollmer B, Meuter C, Janssen PA. R 56865 prevents electrical and mechanical signs of ouabain intoxication in guinea-pig papillary muscle. Eur J Pharmacol. 1987 Oct 6;142(1):137-40. PubMed PMID: 3691632.

6: Koch P, Wilhelm D, Wilffert B, Peters T. R 56865 differentiates between contractile agents with respect to the nifedipine-sensitive component in the isolated rat aorta. Pharmacology. 1989;39(1):11-8. PubMed PMID: 2555825.

7: Daniels MC, ter Keurs HE. Suppressive effects of R 56865 on triggered propagated contractions and triggered arrhythmias in rat cardiac trabeculae. J Cardiovasc Pharmacol. 1992 Aug;20(2):187-96. PubMed PMID: 1381009.

8: Damiano BP, Stump GL, Yagel SK. Investigation of electrophysiologic mechanisms for the antiarrhythmic actions of R 56865 in cardiac glycoside toxicity. J Cardiovasc Pharmacol. 1991 Sep;18(3):415-28. PubMed PMID: 1720842.

9: Le Grand B, Coulombe A, John GW. Late sodium current inhibition in human isolated cardiomyocytes by R 56865. J Cardiovasc Pharmacol. 1998 May;31(5):800-4. PubMed PMID: 9593082.

10: Ichikawa H, Hearse DJ, Coetzee WA. Effects of R-56865 on transient inward current, Na(+)-Ca2+ exchange, and Ca2+ release from SR in cardiac myocytes. Am J Physiol. 1994 Feb;266(2 Pt 2):H511-20. Erratum in: Am J Physiol 1994 Aug;267(2 Pt 2):section H following table of contents. Am J Physiol 1994 Dec;267(6 Pt 3):section H followi. PubMed PMID: 8141352.

11: Heers C, Scheufler E, Wilhelm D, Wermelskirchen D, Wilffert B, Peters T. Differential effect of R 56865 on ouabain binding to isolated sarcolemma and intact atrial tissue of guinea-pig. Br J Pharmacol. 1991 Mar;102(3):675-8. PubMed PMID: 1364838; PubMed Central PMCID: PMC1917946.

12: Wilhelm D, Himmel H, Ravens U, Peters T. Characterization of the interaction of R 56865 with cardiac Na- and L-type Ca channels. Br J Pharmacol. 1991 Oct;104(2):483-9. PubMed PMID: 1665739; PubMed Central PMCID: PMC1908563.

13: Hartmann M, Decking UK. R 56865 exerts cardioprotective properties independent of the intracellular Na(+)-overload in the guinea pig heart. Naunyn Schmiedebergs Arch Pharmacol. 2003 Sep;368(3):160-5. Epub 2003 Sep 2. PubMed PMID: 14513202.

14: Tan HL, Netea AO, Sleeswijk ME, Mazón P, Coronel R, Opthof T, Janse MJ. R 56865 delays cellular electrical uncoupling in ischemic rabbit papillary muscle. J Mol Cell Cardiol. 1993 Sep;25(9):1059-66. PubMed PMID: 8283469.

15: Ver Donck L, Borgers M. Myocardial protection by R 56865: a new principle based on prevention of ion channel pathology. Am J Physiol. 1991 Dec;261(6 Pt 2):H1828-35. PubMed PMID: 1661091.

16: Koch P, Wilhelm D, Wermelskirchen D, Nebel U, Wilffert B, Peters T. Different effects of R 56865 and calcium entry blockers on K+- and noradrenaline-induced contractions and 45Ca uptake in rat aorta. Eur J Pharmacol. 1988 Dec 13;158(3):183-90. PubMed PMID: 3253097.

17: Verscheure Y, Pouget G, De Courtois F, Le Grand B, John GW. Attenuation by R 56865, a novel cytoprotective drug, of regional myocardial ischemia- and reperfusion-induced electrocardiographic disturbances in anesthetized rabbits. J Cardiovasc Pharmacol. 1995 Jan;25(1):126-33. PubMed PMID: 7723341.

18: Vogelgesang R, Scheufler E. R 56865 and flunarizine displace Ca2+ from phosphatidylserine monolayers in a stoichiometric manner. Eur J Pharmacol. 1990 Jan 23;188(1):17-22. PubMed PMID: 2307179.

19: Tegtmeier F, Wilhelm D, Frankow C, Thoné F, Vandeplassche L, Peters T. Effects of R 56865 and phenytoin on mechanical, biochemical, and morphologic changes during ouabain intoxication in isolated perfused rabbit heart. J Cardiovasc Pharmacol. 1992 Sep;20(3):421-8. PubMed PMID: 1279287.

20: Scheufler E, Urenjak J, Osikowska-Evers B, Beile A, Guttmann I, Wilffert B, Tegtmeier F, Peters T. Ouabain-induced changes of calcium and potassium in slices of hippocampus of the rat: comparison to hypoxia and effect of R 56865. Neuropharmacology. 1992 May;31(5):481-6. PubMed PMID: 1528398.